Remedios Castelló

No ORCID on file · 4 papers in corpus
observational 2008
Plasminogen activator inhibitor-1 (PAI-1) 4G/5G polymorphism and endometriosis. Influence of PAI-1 polymorphism on PAI-1 antigen and mRNA expression
Thrombosis research ·doi:10.1016/j.thromres.2008.02.010

INTRODUCTION: Endometriosis is a benign gynecologic disease with a high prevalence. It is a multifactorial and polygenic entity in which the fibrinolytic system may be implicated. The objective of this study was to evaluate the plasminogen …

2007
ANGIOGENESIS IN ENDOMETRIOSIS. INFLUENCE OF THREE FUNCTIONAL VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) POLYMORPHISMS (−460CT, 405GC AND 936CT) IN VEGF EXPRESSION
·doi:10.1111/j.1538-7836.2007.tb00521.x
other 2004
mRNA analysis of several components of the plasminogen activator and matrix metalloproteinase systems in endometriosis using a real-time quantitative RT-PCR assay
Human Reproduction ·doi:10.1093/humrep/deh571

BACKGROUND: The plasminogen activator (PA) and matrix metalloproteinase (MMP) systems are implicated in the establishment of endometriosis. The mechanisms by which these systems are involved in the pathogenesis of this disease are not well …

2003
Quantitative real-time reverse transcription-PCR (RT-PCR) assay for urokinase plasminogen activator, plasminogen activator inhibitor type 1 and tissue metalloproteinase inhibitor type 1 gene expression and protein levels in endometriosis
·doi:10.1111/j.1538-7836.2003.tb04369.x